Live feed08:00:00·26dPRReleasevia QuantisnowBristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple MyelomaByQuantisnow·Wall Street's wire, on your screen.BMY· Bristol-Myers Squibb CompanyHealth Care
